Charleston Laboratories, Inc submitted a request with the U.S. Food and Drug Administration (FDA) for a Pre-Investigational New Drug (Pre-IND) meeting regarding the development of CL-H1T.

Charleston Laboratories, Inc submitted a request with the U.S. Food and Drug Administration (FDA) for a Pre-Investigational New Drug (Pre-IND) meeting regarding the development of CL-H1T. The Company has requested an initial meeting with the U.S. FDA to review the Company’s proposed strategy and plan for conducting clinical trials required for approval of its novel migraine drug candidate, CL-H1T.